Results 191 to 200 of about 21,239 (239)

Tadalafil

Drugs, 2003
black triangle Tadalafil is a selective phosphodiesterase type 5 inhibitor that is effective in men with mild-to-severe erectile dysfunction (ED), including those with diabetes mellitus. black triangle The improvement in the erectile function domain score on the International Index of Erectile Function (IIEF) and the percentage of sexual intercourse ...
Monique, Curran, Gillian, Keating
  +5 more sources

Synchronous fluorescence as a green and selective method for the simultaneous determination of finasteride and tadalafil in dosage form and spiked human plasma.

Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy, 2023
Finasteride and tadalafil are combined in a pharmaceutical capsules called Entadfi™, that has received FAD approval. It was indicated for the management of male benign prostatic hyperplasia-related urinary tract issues.
H. Salem, A. Abdelaziz, M. Galal, Maha Hussien, Nadeen Emad, Asmaa E. Batekh, Mohamed Karem, Deena A. Moukhtar   +7 more
semanticscholar   +1 more source

Tadalafil

Reactions Weekly, 2010
Tadalafil is a selective cyclic guanosine monophosphate-specific phosphodiesterase type 5 inhibitor that is effective in improving exercise ability, the time to clinical worsening and health-related quality of life (HR-QOL) scores in patients with pulmonary arterial hypertension (PAH).
Otto Benkert, Ion Anghelescu, Christoph Fehr, Gerhard Gründer, Philip Heiser, Christoph Hiemke, Christian Lange-Asschenfeldt, M. J. Müller, M. Paulzen, Francesca Regen, Axel Steiger   +10 more
  +6 more sources

Tadalafil

Reactions Weekly, 2011
Tadalafil is PDE5 inhibitor that has recently been approved for the treatment of ED. The mechanism of action of tadalafil is similar to sildenafil and vardenafil through the inhibition of PDE. In both chemical structure and PDE subtype selectivity profile, tadalafil differs markedly from sildenafil and vardenafil.
Alaa A-M, Abdel-Aziz, Yousif A, Asiri, Adel S, El-Azab, Mohamed A, Al-Omar, Takehisa, Kunieda   +4 more
openaire   +3 more sources

Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial

Science Translational Medicine, 2022
Cyclic GMP–phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract maladaptive cardiac changes triggered by diabetes in some but not all studies.
R. Pofi, E. Giannetta, T. Feola, N. Galea, F. Barbagallo, Federica Campolo, Roberto Badagliacca, B. Barbano, F. Ciolina, G. Defeudis, T. Filardi, F. Sesti, M. Minnetti, C. Vizza, P. Pasqualetti, P. Caboni, I. Carbone, M. Francone, C. Catalano, P. Pozzilli, A. Lenzi, M. Venneri, D. Gianfrilli, A. Isidori   +23 more
semanticscholar   +1 more source

Supramolecular Tadalafil Nanovaccine for Cancer Immunotherapy by Alleviating Myeloid-Derived Suppressor Cells and Heightening Immunogenicity.

Small Methods, 2021
Tumor-induced immune suppression mediated by myeloid-derived suppressor cells (MDSCs) and insufficient immunogenicity are two major factors for the poor overall response rate to the immune checkpoint blockade (ICB).
Tian Zhang, Hong-Gang Xiong, Xianbin Ma, Yuan Gao, P. Xue, Yuejun Kang, Zhijun Sun, Zhigang Xu   +7 more
semanticscholar   +1 more source

Cytochrome P450 3A4-mediated pharmacokinetic interaction study between Tadalafil and Canagliflozin using High Performance Thin Layer Chromatography.

Journal of Separation Science, 2022
Diabetes is a known risk factor for sexual dysfunction in men; diabetic men have an increased risk of erectile dysfunction compared to non-diabetic men.
A. B. H. Ali, Fatma A M Abdel-Aal, Azza H. Rageh, A. Mohamed   +3 more
semanticscholar   +1 more source

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.

Journal of the American College of Cardiology
BACKGROUND Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients.
Ekkehard Grünig, P. Jansa, F. Fan, J. Hauser, M. Pannaux, Adele Morganti, H. Rofael, K. Chin   +7 more
semanticscholar   +1 more source

Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study

Circulation
BACKGROUND: We assessed the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, in patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension. METHODS: In the double-
M. Hoeper, Britta Oerke, M. Wißmüller, Hanno H Leuchte, Christian F Opitz, M. Halank, Hans-Juergen Seyfarth, Stephan Baldus, J. Bauersachs, Michael Böhm, H. Ghofrani, Stavros V. Konstantinides, K. Olsson, R. Wachter, C. S. Lam, B. Aminossadati, S. Rosenkranz   +16 more
semanticscholar   +1 more source

Isolation and characterization of a novel tadalafil analogue adulterant, N-cyclohexyl nortadalafil, in a dietary supplement.

Journal of Pharmaceutical and Biomedical Analysis, 2022
A novel tadalafil analogue was detected during routine screening of dietary supplements suspected to be adulterated with an erectile dysfunction drug(s) by using ultra-high-performance liquid chromatography coupled to Quadrupole-Exactive Orbitrap mass ...
Jialing Liu, Jian Sun, Hua-Rong Wei, Hong Yu, Xiang-dong Dai, Qing Hu   +5 more
semanticscholar   +1 more source